These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 26898790)
21. New developments in the management of borderline resectable pancreatic cancer. Sharma J; Ng J; Goodman MD; Saif MW JOP; 2013 Mar; 14(2):123-5. PubMed ID: 23474551 [TBL] [Abstract][Full Text] [Related]
22. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy? Hackert T; Ulrich A; Büchler MW Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331 [No Abstract] [Full Text] [Related]
23. Role of surgery in pancreatic cancer. Buanes TA World J Gastroenterol; 2017 Jun; 23(21):3765-3770. PubMed ID: 28638216 [TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis. Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251 [TBL] [Abstract][Full Text] [Related]
25. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192 [TBL] [Abstract][Full Text] [Related]
26. Role of radiation therapy in patients with resectable pancreatic cancer. Palta M; Willett C; Czito B Oncology (Williston Park); 2011 Jul; 25(8):715-21, 727. PubMed ID: 21874833 [TBL] [Abstract][Full Text] [Related]
27. Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy. Evans DB; Erickson BA; Ritch P Ann Surg Oncol; 2010 Nov; 17(11):2803-5. PubMed ID: 20737218 [No Abstract] [Full Text] [Related]
28. Effects of neoadjuvant combined chemotherapy and radiation therapy on the CT evaluation of resectability and staging in patients with pancreatic head cancer. Kim YE; Park MS; Hong HS; Kang CM; Choi JY; Lim JS; Lee WJ; Kim MJ; Kim KW Radiology; 2009 Mar; 250(3):758-65. PubMed ID: 19164113 [TBL] [Abstract][Full Text] [Related]
29. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases. Wang G; Zhou D Ultrason Sonochem; 2015 Nov; 27():694-702. PubMed ID: 26113389 [TBL] [Abstract][Full Text] [Related]
30. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy. Evans DB; George B; Tsai S Ann Surg Oncol; 2015 Oct; 22(11):3409-13. PubMed ID: 26122369 [No Abstract] [Full Text] [Related]
33. Clinical Management: Resectable Disease. White RR; Lowy AM Cancer J; 2017; 23(6):343-349. PubMed ID: 29189330 [TBL] [Abstract][Full Text] [Related]
34. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography. Mortensen MB Dan Med J; 2012 Dec; 59(12):B4568. PubMed ID: 23290296 [TBL] [Abstract][Full Text] [Related]
35. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786 [TBL] [Abstract][Full Text] [Related]
36. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S; Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127 [TBL] [Abstract][Full Text] [Related]
37. [The value of extended surgery for pancreatic cancer in the context of neoadjuvant therapy]. Zhang TP; Liu YZ; Cao Z Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):481-485. PubMed ID: 32610414 [TBL] [Abstract][Full Text] [Related]
38. Clinical significance of defining borderline resectable pancreatic cancer. Kang MJ; Jang JY; Kwon W; Kim SW Pancreatology; 2018 Mar; 18(2):139-145. PubMed ID: 29274720 [TBL] [Abstract][Full Text] [Related]
39. Borderline resectable pancreatic cancer: More than an anatomical concept. Petrelli F; Inno A; Barni S; Ghidini A; Labianca R; Falconi M; Reni M; Cascinu S; Dig Liver Dis; 2017 Feb; 49(2):223-226. PubMed ID: 27931968 [TBL] [Abstract][Full Text] [Related]